GlassScriptPhysician profile
Edilfavia Uy
NPI 1922332006
$4,890.57
in general payments reported to CMS, 2019-2025
33 companies · $764 in 2025
The $764 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $294 · 2021: $1,049 · 2022: $998 · 2023: $875 · 2024: $910 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,530 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,529.78 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $777.17 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $678.80 | 2020-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $563.50 | 2020-2025 | |
| Lilly USA, LLC | $548.10 | 2020-2025 | Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $405.88 | 2021-2025 | |
| Corcept Therapeutics | $324.28 | 2021-2025 | Korlym |
| Amgen INC. | $305.32 | 2022-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $260.56 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $195.12 | 2021-2023 | Farxiga |
| Chiesi USA, INC. | $91.66 | 2024-2025 | Mycapssa |
| Ultragenyx Pharmaceutical INC. | $75.21 | 2022-2024 | Crysvita |
| Tandem Diabetes Care, INC. | $71.42 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amryt Pharma Holdings LTD | $64.54 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $59.99 | 2023-2025 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $57.06 | 2023-2025 | Strensiq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $56.62 | 2024-2025 | Tymlos |
| Kyowa Kirin, INC. | $43.83 | 2025 | |
| Medtronic, INC. | $41.11 | 2022 | |
| Neurocrine Biosciences, INC. | $34.46 | 2024-2025 | |
| Averitas Pharma INC. | $24.03 | 2024 | Qutenza |
| Sage Therapeutics, LLC | $20.42 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $20.42 | 2025 | Qelbree |
| Exact Sciences Corporation | $18.08 | 2025 | Cologuard Collection Kit |
| Beta Bionics, INC. | $17.67 | 2024 | Ilet Bionic Pancreas |
| Dexcom, INC. | $16.93 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.84 | 2025 | Evkeeza |
| Insulet Corporation | $16.78 | 2022 | |
| Medtronic Minimed, INC. | $15.00 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.81 | 2024 | Xifaxan |
| Endo Pharmaceuticals INC. | $14.63 | 2021 | |
| Livanova USA, INC. | $14.17 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $13.90 | 2023 | Ubrelvy |
| Grt US Holding, INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edilfavia Uy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.